Black Diamond Therapeutics Investor Presentation — June 2019

Document content

Precision Oncology Medicines for

Treatment Resistant Cancers

June 2019Disclaimer

Forward -Looking Statements

Statements in this Presentation that are not statements of historical fact are forward -looking statements. Such forward -looking statements include, without limitation, statements regarding our

research and clinical development plans, business strategy and plans, regulatory matters, objectives of management for future operations, industry trends, market size and opportunity and our

ability to complete certain milestones. Words such as “believe,” “can”, “continue,” “anticipate,” “could,” “estimate,” “plan, ” “predict,” “expect,” “intend,” “will,” “may,” “goal,” “upcoming,” “near

term”, “milestone”, “potential,” “target” or the negative of these terms or similar expressions are intended to identify forw ard-looking statements, though not all forward -looking statements

necessarily contain these identifying words. These forward -looking statements are based on the current beliefs of the Company's management as well as assumptions made by and information

currently available to the Company. Such statements reflect the current expectations and projections of the Company with resp ectto future events and trends and are subject to known and

unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions a bout the Company, including, without limitation: our plans to

research, develop and commercialize our drug candidates, including the timing of our planned Phase 2 portion of TRIDENT -1; the s uccess, cost and timing of our product development activities

and clinical trials, including whether the planned Phase 2 portion of TRIDENT -1 will support the approval of repotrectinib in ROS1+ advanced NSCLC and NTRK + advanced solid tumors; our

ability to obtain and maintain regulatory approval for repotrectinib or any of our other current or future drug candidates, and any related restrictions, limitations, and/or warnings in the labe l of

an approved drug candidate; our expectations regarding the size of target patient populations for our drug candidates, if app roved for commercial use, and any additional drug candidates we

may develop; our ability to obtain funding for our operations; the commercialization of our drug candidates, if approved; our ability to attract collaborators with development, regulatory and

commercialization expertise; our expectations regarding our ability to obtain, maintain, enforce and defend our intellectual property protection for our drug candidates; future agreements with

third parties in connection with the commercialization of repotrectinib , or any of our other current or future drug candidates; the size and growth potential of the markets for our drug candidates ,